Molmir Raises ¥300 Million in Series A Funding

Molmir, a company specializing in drug discovery platform technology that visualizes molecular movement, has successfully raised ¥300 million in a Series A funding round. The funding announcement was made on April 23, 2026. The company, which is based in Japan, focuses on capturing the dynamics of intracellular molecules, particularly those that have been challenging to target in traditional drug discovery processes.

Investors and Funding Details

The Series A round saw participation from a mix of existing and new investors. Returning investors include UntroD Capital Japan, Mitsubishi UFJ Capital, and Ikeda Senshu Capital. New entrants in this round are BP Capital, Nanto Capital Partners, and Higin Capital. This diverse group of investors underscores the confidence in Molmir's innovative approach to drug discovery.

Company Technology and Goals

Molmir's proprietary technologies, "CHEmir" and "MAGmir," are at the forefront of their platform. These technologies integrate analytical chemistry with nuclear magnetic resonance (NMR) solutions to visualize and analyze molecular movements in conditions that closely mimic their natural state. This approach targets dynamic molecules, which make up about 70% of all proteins, offering a significant advantage in drug discovery.

In collaboration with Nara Medical University, Molmir has established the Molecular Dynamics Drug Discovery Joint Research Course. This initiative has already achieved a breakthrough with the acquisition of a hit compound targeting TDP-43, a protein associated with amyotrophic lateral sclerosis (ALS).

Strategic Use of Funds

Molmir plans to allocate the newly raised funds towards several key areas:

  • Research and Development: Focus on developing aggregation control drugs targeting TDP-43 and advancing the molecular dynamics analysis platform.
  • Treatment Development: Working on a treatment for acquired von Willebrand syndrome (AVWS).
  • Collaborations: Promoting joint research and alliances with pharmaceutical companies.
  • Business Development: Strengthening research and business development systems to support the company's growth.

These strategic investments aim to enhance Molmir’s capabilities in drug discovery and expand its collaborative efforts within the pharmaceutical industry.

Molmir's innovative approach and the recent funding are set to propel the company forward in the competitive field of drug discovery, enabling new treatments and solutions for complex medical conditions.